CJC-1295 No-DAC + Ipamorelin is a co-formulated blend pairing a GHRH analog with a selective ghrelin receptor agonist, allowing researchers to study dual-pathway growth hormone stimulation in a single reagent. Supplied as a ≥98% HPLC-verified lyophilized powder for laboratory research use only.
€ 59.99
78 in stock
Third-Party Tested by Janoshik Analytical
Compound Information
Technical specifications
Co-lyophilized blend; keep sealed, dry, and protected from light
Store at a stable temperature; minimize warming/cooling cycles
Aliquot after reconstitution; avoid repeated freeze–thaw cycles
Lyophilized Powder
-20°C preferred; 2–8°C for short-term handling
Reconstituted
2–8°C
This co-formulated blend pairs two growth hormone secretagogues that act through entirely separate receptor systems. CJC-1295 No-DAC (Modified GRF 1–29) engages the GHRH receptor on pituitary somatotrophs, while Ipamorelin — a selective pentapeptide agonist of the ghrelin/GHS-R1a receptor — acts through a parallel pathway and additionally suppresses somatostatin, the brake on GH release. Because the two arms are independent, researchers use this pairing to study convergent and potentially synergistic stimulation of the same downstream output. Ipamorelin’s selectivity is a key part of the design: unlike earlier GHS compounds, it shows minimal cross-activity at cortisol and prolactin pathways, keeping the model cleaner. Supplied as a high-purity co-lyophilized powder for reproducible in-vitro and approved in-vivo work. This product is for laboratory research and development purposes only and must be handled by qualified professionals. Not for human, therapeutic, or diagnostic use.
Dual Receptor Pathways
CJC-1295 acts at the GHRH receptor while Ipamorelin engages GHS-R1a — two independent arms converging on the same output.
Somatostatin Suppression
Ipamorelin additionally dampens somatostatin, the inhibitory brake on GH release — a mechanism CJC-1295 does not share.
Ipamorelin Selectivity
Unlike earlier GHS compounds, Ipamorelin shows minimal cross-activity at cortisol and prolactin pathways, reducing confounds.
Pulsatile Secretion Preserved
Both components clear rapidly, producing a discrete GH pulse rather than sustained elevation — keeping the natural rhythm intact.
Synergy Study Design
The independence of the two pathways makes this a standard pairing for investigating additive or synergistic GH stimulation.
≥98% HPLC Purity
Both components are HPLC-verified and co-lyophilized, ensuring a consistent ratio across every vial.
